ASS1 and colorectal carcinoma: This study confirms that EVO inhibits the Wnt/β-catenin/c-MYC signaling pathway, which results in a decrease in ASS1 expression (the enzyme that limits the rate of arginine synthesis), leading to a reduced availability of intracellular arginine and ultimately hindering the proliferation and movement of CRC cells.